1 min read
Add as a preferred source on Google

Vivos Targets $3.8 Million Annual Revenue Lift From Payer Talks

Management is aiming for positive operating cash flow in early 2027 and cited $200,000 in cash and a need for additional financing.

An unsigned folder rests on an empty clinic reception counter / TokenPost.ai
An unsigned folder rests on an empty clinic reception counter / TokenPost.ai

Vivos Therapeutics, Inc. is targeting about $3.8 million in additional annual revenue through payer contract renegotiations as it works toward positive operating cash flow in early 2027. The effort carries financial and listing risks: management reported $200,000 in cash and said the company needs additional financing.

Management expects payer initiatives and clinical programs to contribute to revenue and margins in the fourth quarter of 2026, with a larger contribution through 2027. The annual revenue target depends on execution, patient participation, payer terms and access to capital.

The company remains out of compliance with Nasdaq’s $1 minimum bid-price requirement. Nasdaq could make a delisting determination if the company’s closing bid stays at or below $0.10 for 10 straight business days.

Management warned of substantial doubt about Vivos’ ability to continue as a going concern, underscoring the financing challenge as it pursues the payer and clinical initiatives.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…